GoodRx Holdings, Inc. (GDRX) Appoints Ian T. Clark to its Board
Get Alerts GDRX Hot Sheet
Join SI Premium – FREE
GoodRx Holdings, Inc. (Nasdaq: GDRX) today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over 35 years of experience in the pharmaceutical and healthcare industries. He formerly served as Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership positions at Novartis, Sanofi, Ivax Pharmaceuticals and G.D. Searle. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies, including Kyverna Therapeutics, Olema Pharmaceuticals, Takeda Pharmaceuticals, Guardant Health and Corvus Pharmaceuticals.
“We believe Mr. Clark’s substantial experience in biopharmaceuticals and biotechnology will be a valuable asset to GoodRx as we look to expand our work with pharma manufacturers to deliver more affordable prices on prescriptions to consumers,” said Trevor Bezdek, GoodRx co-founder and Chairman of the Board. “Additionally, we believe his experience leading publicly traded companies in the healthcare industry will help further fortify our Board’s business acumen and understanding of the complex healthcare business landscape.”
Mr. Clark has joined the Board’s Nominating and Corporate Governance Committee and will also serve as the chairperson of the Board’s newly established Innovation Committee.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deere conference call: 2027 orders up mid-single digits from last year)
- Quanome Technologies forms quantum advisory council and network
- ACRES Commercial Realty says labor dispute is hindering hotel sale
Create E-mail Alert Related Categories
Board Changes, Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share